• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 18.14
  • VXN 24.38
  • VXO 19.94
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
VIVO (Meridian Bioscience Inc.)
Last Trade 19.41 Dividend/Share 0.5 PE Ratio 28.13
Date November 16-2018 Dividend Yield 2.576 Return on Assets 9.52
Change 0.125 ExDividend Date 2018-11-16 Return on Capital null
Bid null Latest EPS 0.56 Price/Sale 3.853
Ask null LatestEPS Date 2018-09-30 Price to Book 4.7
Volume null EPS ttm 0.6900000000000001 Institutional % 94.6
Avg Volume 0.38M Shares Outstanding 42.4M Insider % 3.7
Open 19.15 Float 40.84M Short Ratio null
Prev Close 19.285 Return On Equity 13.83 5 Year Change % -0.030
High 19.52 Consensus EPS 0.17 2 Year Change % 0.204
Low 19.04 No. of Estimate 3.000 1 Year Change % 0.340
52 Week High 19.84 EPS Surprise $ null YTD Change % 0.392
52 Week Low 13.527 EPS Surprise Percent 5.8824 6 Month Change % 0.378
52 Week Change 35.171 EBITDA 10.14M 3 Month Change % 0.311
50 Day MA 15.91039 Revenue 52.28M 1 Month Change % 0.256
200 Day MA Gross Profit 31.79M 5 Day Change % 0.001
Market Cap 822.89M Cash 54.71M 30 Day Change % 0.333
Beta 0.543133 Debt 53.53M Stock Exchange Nasdaq Global Select
Sector Healthcare Revenue Per Share 1 Short Interest 0
Short Date 0 Revenue Per Employee 81692 Short Ratio null
12
Company Profile

Meridian Bioscience, Inc. operates as an integrated life science company. The company primarily engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. Its diagnostic test kits utilize immunodiagnostic technologies, which test samples of blood, urine, stool, and other body fluids or tissues for the presence of antigens and antibodies of specific infectious diseases. The immunodiagnostic technologies include enzyme immunoassay, immunofluorescence, particle agglutination/aggregation, immunodiffusion, complement fixation, and chemical stains. The company also provides transport media that store and preserve specimen samples from patient collection to laboratory testing. In addition, Meridian Bioscience manufactures and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. Further, it involves in the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Meridian Bioscience markets its diagnostic test kits through direct sales force and independent distributors to reference laboratories and hospitals primarily in the United States, Canada, Belgium, France, Holland, Italy, Africa, and the Middle East. The company was founded in 1976 and is based in Cincinnati, Ohio.